Holen Sie sich die Stockscreener-App
16.09
1.39%
0.22
Vorhandelsmarkt:
16.10
0.01
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.87
Offen:
$16.08
24-Stunden-Volumen:
2.07M
Relative Volume:
0.74
Marktkapitalisierung:
$1.69B
Einnahmen:
$2.48B
Nettoeinkommen (Verlust:
$-57.96M
KGV:
-21.21
EPS:
-0.7585
Netto-Cashflow:
$-453.97M
1W Leistung:
-15.18%
1M Leistung:
-18.45%
6M Leistung:
-12.84%
1J Leistung:
-84.36%
1-Tages-Spanne:
$15.70
$16.43
1-Wochen-Bereich:
$15.70
$17.89
52-Wochen-Spanne:
$10.41
$107.77
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
16.09 | 1.66B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - simplywall.st
(SRPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka
Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan
SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView
SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00 - MarketBeat
Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright - MarketBeat
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc. - MarketBeat
Sarepta (NASDAQ: SRPT) COO exercises stock options, lifts holdings to 200,750 shares - Stock Titan
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Understanding the 25.56% Upside Potential - DirectorsTalk Interviews
HC Wainwright & Co. Reiterates Sell Rating for SRPT | SRPT Stock News - GuruFocus
Sarepta Therapeutics 10-K: $2.20B Revenue, $(7.13) EPS - TradingView
Sarepta (NASDAQ: SRPT) details 2025 gene therapy setbacks and big siRNA deal - Stock Titan
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 - Yahoo Finance
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy LaunchAnd What's Next - Yahoo Finance
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Sarepta (SRPT) COO earns 1,875 PSUs tied to performance milestones - Stock Titan
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00 - MarketBeat
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics CEO Ingram to retire by year end - The Mighty 790 KFGO
Sarepta Therapeutics Announces Planned CEO Leadership Transition - The Globe and Mail
Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative - simplywall.st
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings - MarketBeat
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral - BioSpace
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates - Yahoo Finance
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO - Pharmaceutical Executive
Sarepta CEO Ingram Steps Down As Dystrophy Strikes Close To Home - Citeline News & Insights
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Sarepta to present Duchenne therapy data at MDA conference By Investing.com - Investing.com South Africa
Sarepta to present Duchenne therapy data at MDA conference - Investing.com
Sarepta seeks new boss amid Doug Ingram retirement - The Pharma Letter
Sarepta Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sarepta CEO Doug Ingram to retire, with company at a crossroads - BioPharma Dive
Sarepta Therapeutics Reports Earnings Miss and Management Transition - Intellectia AI
Sarepta CEO To Jump Ship After 'Tumultuous' YearSarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Rhumbline Advisers Sells 88,893 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - BioSpace
Sarepta Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-02-26 - Seeking Alpha
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):